Cargando…

Histone Deacetylase Inhibitor Panobinostat Benefits the Therapeutic Efficacy of Oncolytic Herpes Simplex Virus Combined with PD-1/PD-L1 Blocking in Glioma and Squamous Cell Carcinoma Models

Background: Combination therapy has been widely explored for oncolytic virus (OV), as it can be met with tumor resistance. The HDAC inhibitor (HDACi) panobinostat is a potent pan-deacetylase inhibitor which blocks multiple cancer-related pathways and reverses epigenetic events in cancer progression....

Descripción completa

Detalles Bibliográficos
Autores principales:	Wu, Yinglin, Chen, Xiaoqing, Wang, Lei, Zhou, Xusha, Liu, Yonghong, Ji, Dongmei, Ren, Peigen, Zhou, Grace Guoying, Zhao, Jing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9781547/ https://www.ncbi.nlm.nih.gov/pubmed/36560800 http://dx.doi.org/10.3390/v14122796

Ejemplares similares

Enhancing Therapeutic Efficacy of Oncolytic Herpes Simplex Virus with MEK Inhibitor Trametinib in Some BRAF or KRAS-Mutated Colorectal or Lung Carcinoma Models
por: Zhou, XuSha, et al.
Publicado: (2021)

Histone deacetylase inhibitors enhance oncolytic herpes simplex virus therapy for malignant meningioma
por: Kawamura, Yoichiro, et al.
Publicado: (2022)

Degradation of Herpes Simplex Virus-1 Viral miRNA H11 by Vaccinia Virus Protein VP55 Attenuates Viral Replication
por: Zou, Weixuan, et al.
Publicado: (2020)

Histone Deacetylase Inhibitors Improve the Replication of Oncolytic Herpes Simplex Virus in Breast Cancer Cells
por: Cody, James J., et al.
Publicado: (2014)

Oncolytic herpes simplex virus delivery of dual CAR targets of CD19 and BCMA as well as immunomodulators to enhance therapeutic efficacy in solid tumors combined with CAR T cell therapy
por: Liu, Yuanyuan, et al.
Publicado: (2022)

High accumulation of Mx2 renders limited multiplication of oncolytic herpes simplex virus-1 in human tumor cells
por: Ren, Yong, et al.
Publicado: (2021)

Oncolytic herpes simplex virus and immunotherapy
por: Ma, Wenqing, et al.
Publicado: (2018)

Cooperation of Oncolytic Herpes Virotherapy and PD-1 Blockade in Murine Rhabdomyosarcoma Models
por: Chen, Chun-Yu, et al.
Publicado: (2017)

Targeting triple-negative breast cancer cells with the histone deacetylase inhibitor panobinostat
por: Tate, Chandra R, et al.
Publicado: (2012)

Retargeting Strategies for Oncolytic Herpes Simplex Viruses
por: Campadelli-Fiume, Gabriella, et al.
Publicado: (2016)

PD-L1 upregulation in myeloma cells by panobinostat in combination with interferon-γ
por: Iwasa, Masami, et al.
Publicado: (2019)

Histone Deacetylase Inhibitors Reduce the Number of Herpes Simplex Virus-1 Genomes Initiating Expression in Individual Cells
por: Shapira, Lev, et al.
Publicado: (2016)

Herpes simplex virus 1 as an oncolytic viral therapy for refractory cancers
por: Scanlan, Hayle, et al.
Publicado: (2022)

HIV anti-latency treatment mediated by macromolecular prodrugs of histone deacetylase inhibitor, panobinostat
por: Zuwala, Kaja, et al.
Publicado: (2016)

Advances in oncolytic herpes simplex virus and adenovirus therapy for recurrent glioma
por: Hu, Mingming, et al.
Publicado: (2023)

Oncolytic Herpes Simplex Virus-Based Therapies for Cancer
por: Aldrak, Norah, et al.
Publicado: (2021)

Oncolytic virus and PD-1/PD-L1 blockade combination therapy
por: Chen, Chun-Yu, et al.
Publicado: (2018)

Influence of a novel histone deacetylase inhibitor panobinostat (LBH589) on the growth of ovarian cancer
por: Garrett, Leslie A., et al.
Publicado: (2016)

Panobinostat, a histone deacetylase inhibitor, suppresses leptomeningeal seeding in a medulloblastoma animal model
por: Phi, Ji Hoon, et al.
Publicado: (2017)

Expression of histone deacetylase (HDAC) family members in bortezomib-refractory multiple myeloma and modulation by panobinostat
por: Cheng, Tiewei, et al.
Publicado: (2021)

Generation of an Oncolytic Herpes Simplex Virus 1 Expressing Human MelanA
por: Boscheinen, Jan B., et al.
Publicado: (2019)

The complex relationship between integrins and oncolytic herpes Simplex Virus 1 in high-grade glioma therapeutics
por: Rivera-Caraballo, Kimberly Ann, et al.
Publicado: (2022)

Presage of oncolytic virotherapy for oral cancer with herpes simplex virus
por: Yura, Yoshiaki
Publicado: (2017)

The Current State of Oncolytic Herpes Simplex Virus for Glioblastoma Treatment
por: Nguyen, Hong-My, et al.
Publicado: (2021)

Replication and Spread of Oncolytic Herpes Simplex Virus in Solid Tumors
por: Hong, Bangxing, et al.
Publicado: (2022)

The Histone Deacetylase Inhibitor LBH589 (Panobinostat) Modulates the Crosstalk of Lymphocytes with Hodgkin Lymphoma Cell Lines
por: Klein, Jan M., et al.
Publicado: (2013)

The Effect of Herpes Simplex Virus-Type-1 (HSV-1) Oncolytic Immunotherapy on the Tumor Microenvironment
por: Uche, Ifeanyi Kingsley, et al.
Publicado: (2021)

Exosomes containing miRNAs targeting HER2 synthesis and engineered to adhere to HER2 on tumor cells surface exhibit enhanced antitumor activity
por: Wang, Lei, et al.
Publicado: (2020)

Oncolytic herpes simplex viruses for the treatment of glioma and targeting glioblastoma stem-like cells
por: Kardani, Kimia, et al.
Publicado: (2023)

Panobinostat Induced Spatial In Situ Biomarkers Predictive of Anti-PD-1 Efficacy in Mouse Mammary Carcinoma
por: Tatarova, Zuzana, et al.
Publicado: (2023)

The histone deacetylase inhibitor panobinostat is a potent antitumor agent in canine diffuse large B-cell lymphoma
por: Dias, Joana N.R., et al.
Publicado: (2018)

A Phase II Trial of a Histone Deacetylase Inhibitor Panobinostat in Patients With Low-Grade Neuroendocrine Tumors
por: Jin, Ning, et al.
Publicado: (2016)

Molecular Mechanism of the Cell Death Induced by the Histone Deacetylase Pan Inhibitor LBH589 (Panobinostat) in Wilms Tumor Cells
por: Yan-Fang, Tao, et al.
Publicado: (2015)

Treatment of breast cancer stem cells with oncolytic herpes simplex virus
por: Li, J, et al.
Publicado: (2012)

Preclinical Evaluation of Engineered Oncolytic Herpes Simplex Virus for the Treatment of Neuroblastoma
por: Gillory, Lauren A., et al.
Publicado: (2013)

Modulation of the Intratumoral Immune Landscape by Oncolytic Herpes Simplex Virus Virotherapy
por: Yin, Jie, et al.
Publicado: (2017)

Herpes Simplex Virus Oncolytic Immunovirotherapy: The Blossoming Branch of Multimodal Therapy
por: Menotti, Laura, et al.
Publicado: (2020)

Oncolytic herpes simplex virus infects myeloma cells in vitro and in vivo
por: Ghose, Jayeeta, et al.
Publicado: (2021)

Histone deacetylase inhibitors vorinostat and panobinostat induce G1 cell cycle arrest and apoptosis in multidrug resistant sarcoma cell lines
por: Bernhart, Eva, et al.
Publicado: (2017)

Absence of CD28-CTLA4-PD-L1 Costimulatory Molecules Reduces Herpes Simplex Virus 1 Reactivation
por: Matundan, Harry H., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_72af4oqbl3o1objtk73lf11b5q